Serenity Pharmaceuticals LLC

Rivus Pharmaceuticals Inc. already had its lead Controlled Metabolic Accelerator (CMA), known as HU6, in a Phase IIa clinical trial last year when it raised $35m in series A venture capital. Now, wit

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Continues Development Of Novel S

Ferring Pharmaceuticals Inc. has turned to the US FDA's citizen petition process to keep Serenity Pharmaceuticals LLC from being the first to market with a desmopressin drug approved for nocturi

An FDA advisory panel concluded that the limited benefits of Serenity Pharmaceuticals LLC / Allergan PLC ’s desmopressin nasal spray for nocturia – essentially cutting down nighttime trips to the